Edesa Biotech, Inc. (EDSA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Edesa Biotech reported revenue of $0. Net income was -$7.2M. Operating activities generated -$7.3M of cash, leaving -$7.3M of free cash flow. At fiscal year end, Edesa Biotech held $13.5M in total assets against $1.1M in total liabilities, including $10.8M of cash and equivalents.
Open the full interactive Edesa Biotech financials → Quarterly statements, key ratios, valuation history and price charts.
Edesa Biotech Key Stats
| Share Price | $2.85 |
|---|---|
| Market Cap | $25.7M |
| 52-Week Range | $0.80 – $18.28 |
| Shares Outstanding | 9.0 million (basic, 2026 Q3) |
Edesa Biotech Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $328,801 | $0 | $780,000 | $0 | $0 | $0 |
| Gross Profit | $311,200 | $0 | — | — | — | — |
| Operating Income | -$6.4M | -$23.7M | -$18.4M | -$9.2M | -$7.0M | -$7.9M |
| Pre-Tax Income | -$6.4M | -$13.3M | -$17.5M | -$8.4M | -$6.2M | -$7.2M |
| Income Tax | $800 | $800 | $800 | $800 | $800 | $800 |
| Net Income | -$6.4M | -$13.3M | -$17.5M | -$8.4M | -$6.2M | -$7.2M |
| Diluted EPS | -$5.18 | -$7.70 | — | — | — | — |
Edesa Biotech Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.2M | -$2.2M | -$4.2M | -$5.4M |
Edesa Biotech Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.2M | $7.8M | $7.1M | $5.4M | $1.0M | $10.8M |
| Current Assets | $8.1M | $12.1M | $9.1M | $6.4M | $1.7M | $11.5M |
| Total Assets | $10.8M | $14.6M | $11.6M | $8.9M | $3.8M | $13.5M |
| Current Liabilities | $1.5M | $1.5M | $2.1M | $1.8M | $1.8M | $1.1M |
| Total Long-Term Debt | — | — | $43,662 | — | — | — |
| Total Liabilities | $1.7M | $1.5M | $2.2M | $1.8M | $1.8M | $1.1M |
| Shareholders' Equity | $6.6M | $13.1M | $9.4M | $7.0M | $2.0M | $12.5M |
Edesa Biotech Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.0M | -$13.7M | -$12.3M | -$6.6M | -$4.9M | -$7.3M |
| Cash From Investing | $19,073 | -$6,146 | -$5,656 | $0 | — | — |
| Cash From Financing | $7.1M | $14.2M | $11.6M | $4.8M | $592,031 | $17.0M |
| Free Cash Flow | -$5.0M | -$13.7M | -$12.3M | -$6.6M | -$4.9M | -$7.3M |
Figures from Edesa Biotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Edesa Biotech financials page for every line item.
Edesa Biotech Company Profile
| Ticker | EDSA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Markham |
| Fiscal Year End | September 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001540159 |
Frequently Asked Questions
What was Edesa Biotech's revenue in fiscal 2025?
Edesa Biotech (EDSA) reported revenue of $0 for fiscal 2025.
What is Edesa Biotech's annual revenue history?
Edesa Biotech's annual revenue by fiscal year: 2020: $328,801; 2021: $0; 2022: $780,000; 2023: $0; 2024: $0; 2025: $0.
What was Edesa Biotech's net income in fiscal 2025?
Edesa Biotech reported net income of -$7.2M for fiscal 2025.
How much free cash flow did Edesa Biotech generate in fiscal 2025?
Edesa Biotech generated -$7.3M of free cash flow in fiscal 2025.
What was Edesa Biotech's revenue last quarter?
In its most recent reported quarter (2026 Q3), Edesa Biotech reported revenue of $0.
How many shares of Edesa Biotech are outstanding?
Edesa Biotech reported a weighted average of 9.0 million basic shares outstanding in 2026 Q3.
What is Edesa Biotech's market cap?
Based on its latest closing price, Edesa Biotech (EDSA) has a market capitalization of about $25.7M.
When does Edesa Biotech's fiscal year end?
Edesa Biotech's fiscal year end, as registered with the SEC, is September 30.
Where is Edesa Biotech headquartered?
Edesa Biotech lists its business address in Markham in its SEC filings.